Skip to main content

Table 1 Treatment recommendations

From: Dedicated call center (SOS-HAE) for hereditary angioedema attacks: study protocol for a randomised controlled trial

Treatment Recommendations
Vital distress - Immediately and as soon as possible:
  - Administer icatibant (Firazyr®): 30 mg subcutaneously or
  - plasma-derived C1-INH (Bérinert®): 20 UI/kg intravenously
  - Switch the call to the local SAMU to send French EMS
  - Gain control of upper airway
Severe attacks - Immediately and as soon as possible:
 Laryngeal - Administer icatibant (Firazyr®): 30 mg subcutaneously or
 Facial - plasma-derived C1-INH (Bérinert®): 20 UI/kg intravenously
 Abdominal - If treatments are unavailable at home, switch the call to the local SAMU to send an ambulance headed towards a hospital with specific treatments available or being able to get them by French EMS
  - Gain control of upper airway
Non-severe attacks (members, genitals) - Tranexamic acid: 1 g/6 h except for patients who are breastfeeding or have thromboembolic pathology
Surveillance in all cases Monitoring by phone 30 min, 1 h, 4 h, 12 h and 24 h after the beginning of the attack
  Advice to call back SOS-HAE call centre in case of secondary worsening